Drug Trial Radar · NCT03808922
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
Last checked: Nov 19, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
274
Planned (sponsor's estimate)
Start
May 23, 2019
Primary completion
Sep 1, 2028
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Ansun Biopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.
Conditions
- Lower Respiratory Tract Infection
- Parainfluenza
- Immunocompromised
- COVID-19
Interventions
DAS181Drug
DAS181 4.5mg nebulized qd x 7 OR 10 days
PlaceboDrug
Placebo nebulized qd x 7 OR 10 days
DAS181 COVID-19Drug
DAS181 4.5mg nebulized q12h/day x 7 OR 10 days
DAS181 OLDrug
DAS181 4.5mg nebulized qd x 7 OR 10 days ≥ 40kg DAS181 2.5mg nebulized qd x 7 OR 10 days \< 40kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of subjects who Return to Room Air (RTRA) (main study)Time frame: by Day 28
- Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)Time frame: Day 14
Locations
28 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope cancer Center
Duarte, California · Recruiting
University of California Davis Health System
Sacramento, California · Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois · Recruiting
University of Iowa Health Care
Iowa City, Iowa · Recruiting
University of Kansas Medical Center
Fairway, Kansas · Recruiting
The Johns Hopkins Hospital
Baltimore, Maryland · Withdrawn
Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Washington University
St Louis, Missouri · Withdrawn
Weill Cornell Medical College
New York, New York · Recruiting
Duke University
Durham, North Carolina · Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio · Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma · Recruiting
Oregon Health & Science University
Portland, Oregon · Withdrawn
University of Pittsburgh Medical Center Health System
Pittsburgh, Pennsylvania · Recruiting
UT Southwestern Medical Center
Dallas, Texas · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
MD Anderson
Houston, Texas · Recruiting
VCU Health System
Richmond, Virginia · Recruiting
Seattle Children's Hospital
Seattle, Washington · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Recruiting
Froedtert Medical College Pulmonary Clinic
Milwaukee, Wisconsin · Completed
Westmead Hospital
Sydney, New South Wales, Australia · Terminated
Shanghai Pulmonary Hospital
Yangpu, Shanghai Municipality, China · Terminated
Seoul National University Hospital
Seoul, Gyeonggi-do, South Korea · Terminated
Samsung Medical Center
Seoul, Gyeonggi-do, South Korea · Terminated
National Cheng Kung University Hospital
Tainan, Tainan, Taiwan · Terminated
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.